Evaxion and the European Investment Bank (EIB) are in advanced discussions about conversion of €3.5 million out of Evaxion's €7 million loan with EIB into an equity-type instrumentSuch conversion is expected to increase Evaxion's equity by $3.7 million immediately upon completionThe conversion would significantly enhance Evaxion's equity and capital structure. As such, it is an important part of Evaxion's plan on ensuring ongoing compliance with the Nasdaq listing requirements An agreement is expected to be ...

COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results. Business highlights (since last quarterly update) Since the second quarter 2024 business update, we have continued to execute strongly on our strategy and plans with several major milestones achieved. Key highlights include: Significant expansion of the ...

COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 13:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is ...

Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked AI-Immunology™ vaccine targets, thereby linking AI-vaccine design with real-world evidence This underscores the platform's unique potential in selecting effective vaccine targets The ongoing generation of relevant clinical data allows for continuous refinement of AIImmunology™ thereby broadening the commercial po ...

Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through iterative learning and the integration of advanced bioinformatics and machine learning techniques In the ongoing phase 2 trial with personalized cancer vaccine EVX-01, 79% of the AIImmunology™ predicted vaccine targets triggered a tumor-specific immune response, a significant increase from 58% observed in the E ...

The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein prediction feature The launch will expectedly improve Evaxion's ability to fast and effectively discover AI-derived novel vaccines and is expected to further solidify the strong interest seen in AI-Immunology™ from potential partners New data demonstrating the improved performance of EDEN™ will be presented today at the European Conference on Computational Bi ...

COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AIImmunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CEST/08:30 EDT presenting the update and results as well as ...

Precision in Vaccine Target Prediction: These advancements in EvaxMHC's performance are anticipated to further enhance Evaxion's ability to accurately predict vaccine targets Christian Kanstrup, Evaxion's CEO, comments: "Our results demonstrate significant improvements in the prediction of peptide-MHC interactions, particularly for MHC class II molecules, which have historically been difficult to predict accurately. With this advancement on AI-Immunology™ we now have a more reliable and effective tool for d ...

affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospe ...

A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion's personalized cancer vaccine, EVX-01, in patients with metastatic melanoma The findings also demonstrate strong and clinically relevant immune responses after EVX-01 administration to metastatic melanoma patients co-treated with anti-PD-1 standard of care The clinical study results substantiate the precision and predictive power of Evaxion's AI-Immunology™ platform Evaxion has adv ...